Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Korean Pharma Highlights R&D Progress, 2020 Strategy At JPM

Obesity Emerges As Key Theme

Executive Summary

Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.

You may also be interested in...



Changes Encourage Celltrion And Nan Fung To Bet On China Biosimilars Opportunity

Despite increasing competition, Celltrion has leapt into China's growing biosimilar market through a joint venture with Nan Fung, and another draw could lie in the biologics contract manufacturing potential in the country’s developing Greater Bay Area.

Hanmi Faces Another Licensee U-Turn, This Time Janssen On Obesity/Diabetes Drug

Janssen has returned the rights to an obesity/diabetes drug to originator Hanmi, after Phase II studies failed to achieve glycemic control targets and reflecting development difficulties in the sector. This is the fourth time for the Korean firm to face a U-turn of licensed out compounds. 

Korea Q2 Roundup: In-House Drugs, Exports Help Hanmi, Daewoong, Boryung

Among the strong performers, Hanmi benefitted from growth for in-house-developed metabolic disease drugs and China cold syrup sales and Daewoong was boosted by exports of botulinum toxin, while Boryung reported record quarterly sales helped by its flagship antihypertensive.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC141487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel